Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bicycle Therapeutics PLC Sponsored ADR BCYC

Healthcare  —  Biotechnology
3.69 (0.04) (1.07%) as of 25 Sep
Market cap
$199.4M
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Business Profile

Updated before January 2025

Company Overview

Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies based on its proprietary bicyclic peptide technology. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom, with additional operations in Lexington, Massachusetts, USA. Bicycle Therapeutics was co-founded by Sir Gregory Winter, a Nobel laureate, and Professor Christian Heinis, both of whom are pioneers in the field of peptide therapeutics. The company is led by a team of seasoned executives, including Kevin Lee, Ph.D., who serves as the Chief Executive Officer. Dr. Lee brings extensive experience in drug discovery and development, having held leadership roles at major pharmaceutical companies.

Core Business Segments

Bicycle Therapeutics focuses on the development of a novel class of therapeutics known as Bicycle® peptides. These peptides are synthetic, short-chain molecules that combine the pharmacological properties of biologics with the manufacturing simplicity of small molecules. The company’s core business segments include:

Oncology

Bicycle Therapeutics is primarily focused on oncology, leveraging its proprietary technology to develop targeted cancer therapies. Key products in this segment include:

  • BT5528: A Bicycle Toxin Conjugate (BTC) targeting EphA2, a protein overexpressed in various cancers.
  • BT8009: Another BTC targeting Nectin-4, a protein associated with bladder and other cancers.
  • BT7480: A Bicycle tumor-targeted immune cell agonist (Bicycle TICA™) targeting Nectin-4 and CD137 to stimulate an immune response against tumors.

Other Therapeutic Areas

While oncology remains the primary focus, Bicycle Therapeutics is also exploring applications in other therapeutic areas, including:

  • Antibacterial Therapies: Developing Bicycle peptides to combat antibiotic-resistant bacteria.
  • Cardiovascular Diseases: Investigating the potential of Bicycle peptides in treating cardiovascular conditions.

Business Model

Bicycle Therapeutics operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Collaborations and Licensing Agreements: Bicycle Therapeutics has established partnerships with leading pharmaceutical companies, including AstraZeneca, Genentech, and Ionis Pharmaceuticals. These collaborations provide funding for research and development while allowing the company to leverage the expertise and resources of its partners.
  • Clinical Development: The company invests heavily in advancing its pipeline of Bicycle-based therapeutics through clinical trials, aiming to bring innovative treatments to market.
  • Intellectual Property: Bicycle Therapeutics holds a robust portfolio of patents covering its proprietary technology, ensuring a competitive edge in the biopharmaceutical industry.

Strategic Direction

Bicycle Therapeutics is committed to advancing its pipeline of Bicycle-based therapeutics and expanding its platform’s applications. Key strategic priorities include:

  • Pipeline Expansion: The company aims to broaden its therapeutic focus beyond oncology, exploring opportunities in infectious diseases, cardiovascular conditions, and other areas.
  • Global Reach: Bicycle Therapeutics is focused on expanding its presence in key markets, particularly in North America and Europe.
  • Sustainability Goals: The company is dedicated to sustainable practices in its operations, including reducing its environmental footprint and promoting ethical sourcing of materials.
  • Innovation: Bicycle Therapeutics continues to invest in research and development to enhance its platform technology and discover new therapeutic candidates.

Competitive Landscape

Bicycle Therapeutics operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Peptide Therapeutics Companies: Companies like PeptiDream and PolyPeptide Group are also focused on developing peptide-based therapies.
  • Large Biopharmaceutical Firms: Established players like Amgen, Genentech, and AstraZeneca compete in overlapping therapeutic areas, particularly oncology.
  • Emerging Biotech Firms: Startups and smaller biotech companies developing novel therapeutic modalities pose additional competition.

Risk Factors

Bicycle Therapeutics faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of the company’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s revenue is heavily reliant on its partnerships and licensing agreements.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of raw materials and manufacturing processes.
  • Competition: Intense competition in the biopharmaceutical industry could impact market share and pricing.

Recent Developments

Bicycle Therapeutics has made significant progress in advancing its pipeline and expanding its platform technology. Recent developments include:

  • Clinical Trial Updates: The company has reported promising interim results from Phase I/II trials of BT5528 and BT8009, demonstrating efficacy and safety in treating certain cancers.
  • New Collaborations: Bicycle Therapeutics recently entered into a partnership with Ionis Pharmaceuticals to develop targeted therapies for cardiovascular diseases.
  • Platform Enhancements: The company has introduced new capabilities to its Bicycle platform, enabling the discovery of next-generation therapeutics.
  • Global Events: The COVID-19 pandemic has underscored the importance of innovative therapies, driving increased interest in Bicycle Therapeutics’ platform.

Investment Considerations

Investors considering Bicycle Therapeutics should weigh the following factors:

Strengths

  • Innovative Technology: The company’s proprietary Bicycle platform offers a unique approach to drug development.
  • Strong Pipeline: Bicycle Therapeutics has a robust pipeline of clinical-stage candidates with significant market potential.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies provide financial stability and access to additional resources.

Risks

  • Early-Stage Company: As a clinical-stage company, Bicycle Therapeutics has yet to commercialize any products, making it a high-risk investment.
  • Regulatory and Clinical Risks: The success of the company’s pipeline depends on regulatory approvals and clinical trial outcomes.
  • Market Competition: Intense competition in the biopharmaceutical industry could impact the company’s growth prospects.

Conclusion

Bicycle Therapeutics PLC Sponsored ADR is a pioneering biopharmaceutical company with a unique platform technology and a strong focus on oncology. While the company faces significant risks as a clinical-stage entity, its innovative approach and strategic partnerships position it well for future growth. With a robust pipeline and a commitment to expanding its therapeutic focus, Bicycle Therapeutics is poised to make a significant impact in the biopharmaceutical industry.